Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07999415 in healthy adult participants
NCT06965465Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Modality
- Biologic (Biologic)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing PF-07999415 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at Day 120. Started Jun 2025; status: completed.
02
Drugs
PF-07999415
Beyond the preview
Go deeper on NCT06965465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965465.